訂購信息：
|
目錄號 |
產品名稱 |
規(guī)格 |
售價 |
|
X13116 |
Temozolomide |
10mg |
￥420.00 |
|
X13117 |
Temozolomide |
50mg |
￥840.00 |
|
X13118 |
Temozolomide |
100mg |
￥1,344.00 |
特性說明：
|
CAS號 |
85622-93-1 |
|
分子式 |
C6H6N6O2 |
|
分子量 |
194.15 g/mol |
|
溶解度 |
>6.6mg/mL in DMSO |
|
純度 |
98.00% |
|
運輸條件 |
冰袋運輸 |
|
儲存條件 |
-20°C保存 |
產品說明：
Temozolomide, an alkylating agent, is a DNA damage inducer.
1、Cell experiment
Cell lines：SK-LMS-1 leiomyosarcoma (MGMT-/p53+), Ewing sarcoma A-673 and GIST-T1 (both lines with MGMT+/p53- phenotype), and glioblastoma T98G (MGMT+/p53+)
Preparation method：The solubility of this compound in DMSO is >6.6mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.
Reacting condition：62.5, 125, 250 and 500 μM; 72 h
Applications：In SK-LMS-1 cells, Temozolomide inhibited proliferative activity of SK-LMS-1 cells. A-673 cells was most sensitive to temozolomide, the effect was time- and dose-dependent. Preincubation of Ewing sarcoma cells with O6-benzylguanine potentiated the cytotoxic effect of the alkylating agent and reduced viability of tumor cells. GIST-T1 cells were insensitive to temozolomide.
2、Animal experiment
Animal models：PARP1 wild‐type (WT) and PARP1 knock‐out (KO) mice
Dosage form：68 mg/kg; once daily for 5 days; orally administrated
Application：In PARP1 WT mice, temozolomide significantly lowered concentrations of NAD+ in the liver when compared with the control group (by 22%, p = 0.02). In the livers of PARP1 KO mice, there was also a statistically significant reduction in NAD+ in the temozolomide‐only group when compared with the control (by 22%, p = 0.03).
Other notes：Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
注意事項：
為了您的安全和健康，請穿實驗服并戴一 次性手套操作。
本產品僅供科研使用，不可用于臨床診斷應用或其他用途。
